Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17090836 | 1.00 | TSHR (0.50) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL2917826 | 1.00 | TSHR (0.50) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL2920003 | 1.00 | TSHR (0.50) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL10984369 | 1.00 | TSHR (0.50) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL17090784 | 1.00 | TSHR (0.50) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL2922266 | 1.00 | TSHR (0.50) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL2918415 | 1.00 | TSHR (0.50) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL2920815 | 1.00 | TSHR (0.50) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL2917797 | 1.00 | TSHR (0.50) | TSHRTHRBLMNAALDH1A1HSD17B10 | |
| SCHEMBL618296 | 1.00 | TSHR (0.50) | TSHRTHRBLMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536767-A | Supported chromium-based polyethylene catalyst and preparation method thereof | 中国石油化工股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2921499-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
| EP-2821395-A2 | Novel disulfonic acid ester as an additive for an electrolyte for a lithium secondary battery | Wako Pure Chemical Industries, Ltd. (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-8716513-B2 | Process for production of bis-quaternary ammonium salt, and novel intermediate | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-05-06 | — | — | US | disclosed |
| EP-2463266-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | Wako Pure Chemical Industries, Ltd. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120130107-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| EP-1688423-B1 | Silylation of hydroxyl group-containing compounds | SHINETSU CHEMICAL CO (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-1688423-A1 | Silylation of hydroxyl group-containing compounds | Shin-Etsu Chemical Co., Ltd. (JP) | 2006-08-09 | — | — | EP | disclosed |
| EP-1334975-B1 | Silylation of hydroxyl group-containing compounds | SHINETSU CHEMICAL CO (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-6875880-B2 | Silylation of hydroxyl groups | SHIN-ETSU CHEMICAL, CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| EP-1334975-A1 | Silylation of hydroxyl group-containing compounds | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-20030139619-A1 | Silylation of hydroxyl groups | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-07-24 | — | — | US | disclosed |
| US-5099006-A | ompounds for use in paints, for waterproofing, as adhesion promoters, mordants, sizing agents and intermediates | RHONE-POULENC INC. (US) | 1992-03-24 | — | — | US | disclosed |
| US-5017694-A | With silanol-type compounds | RHONE-POULENC, INC. (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0324671-A2 | Alkoxy-type derivatives of trivalent metals of group 3b, and their preparation | RHONE-POULENC CHIMIE (FR) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | POLM, POLRMT, RNMT | TSHR 495/4885THRB 936/4885LMNA 233/4885 |
| US-20120130107-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | ASS1, C1S, FHIT | TSHR 689/4885THRB 2151/4885LMNA 4498/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | TSHR 551/4885THRB 1506/4885LMNA 214/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | TSHR 411/4885THRB 1249/4885LMNA 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.